Home
Clinical Resources Search
PQI: PARP Inhibitor Eligibility in Ovarian Cancer

PARP Inhibitor Eligibility in Ovarian Cancer

Last Updated: September 6, 2023

By: Martina Fraga, PharmD

About this PQI

The purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI